Seng H. Cheng

SVP, Head of Research and Product Development

Seng H. Cheng, Ph.D., is Senior Vice President, Head of Research and Product Development of Alexion, AstraZeneca Rare Disease


About Seng

Seng H. is responsible for drug discovery, process development and clinical supply as well as clinical biomarkers and bioanalytical discovery, rare disease diagnostics and bioinformatics, supporting Alexion’s pipeline from target discovery through post-marketing.

Seng was previously Senior Vice President & Chief Scientific Officer of the Rare Disease Research Unit at Pfizer. Prior to Joining Pfizer, he held roles including Group Vice President of Genetic Diseases Science at Genzyme as well as the Global Head of Research of Rare Diseases at Sanofi. He has contributed to the development of several medicines for patients with rare diseases, co-authored over 280 research articles and reviews and is a named co-inventor on sixty-four issued US patents in the area of biotechnology.

Seng obtained his BSc and PhD degrees in Biochemistry at the University of London and trained as a postdoctoral fellow in the field of tumor biology at the National Institute of Medical Research, U.K.

Tanner, diagnosed with HPP at 4 days old, with a stuffed animal
My hope for Tanner in the future is that he enters into adulthood. I kind of hope that he will be a doctor, and maybe help kids like doctors have helped him.”